


Enclosure: Listing of Claims

**THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER
OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION,
DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO
DEPOSIT ACCOUNT NO. 08,3220.**

LISTING OF CLAIMS

- 1 - (currently amended)

A method-of-treating a living animal for inhibition of progression or alleviation of a condition which is alleviated by a 5HT₃ or neuronal nicotinic receptor antagonist, selected from emesis, cerebellar tremor, appetite disorders, and irritable bowel syndrome, comprising the step of administering to the said living animal an amount of a 1-aminoalkylcyclohexane compound selected from the group consisting of those of the formula



wherein R* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$

wherein $n+m = 0, 1, \text{ or } 2$

wherein R¹ through R⁷ are independently selected from the group consisting of hydrogen and lower-alkyl C₁-C₆, wherein R⁸ and R⁹ are independently selected from the group consisting of hydrogen and lower-alkyl C₁-C₆ or together represent lower-alkylene $-(CH_2)_x-$ wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, which is effective for the said purpose.

- 2 - (previously presented)

A method of Claim 1 wherein at least R¹, R⁴, and R⁵ are lower-alkyl.

US Serial No. 09/597,102
Response and Amendment After Final of June 9, 2006
MERZ 30

- 3 - (previously presented)

A method of Claim 2 wherein R¹ through R⁵ are methyl.

- 4 - (previously presented)

A method of Claim 1 wherein R¹ is ethyl.

- 5 - (previously presented)

A method of Claim 1 wherein R² is ethyl.

- 6 - (previously presented)

A method of Claim 1 wherein R³ is ethyl.

- 7 - (previously presented)

A method of Claim 1 wherein R⁴ is ethyl.

- 8 - (previously presented)

A method of Claim 1 wherein R⁵ is ethyl.

- 9 - (previously presented)

A method of Claim 1 wherein R⁵ is propyl.

- 10 - (previously presented)

A method of Claim 1 wherein R⁶ or R⁷ is methyl.

- 11 - (previously presented)

A method of Claim 1 wherein R⁶ or R⁷ is ethyl.

- 12 - (currently amended)

A method of Claim 2 wherein X_x is 4 or 5.

- 13 - (currently amended)

A method of Claim 3 wherein X_x is 4 or 5.

- 14 - (canceled)

- 15 - (previously presented)

A method of Claim 1 wherein the compound is selected from the group consisting of

1-Amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane,
1-Amino-1,3,3,5(trans)-tetramethylcyclohexane (axial amino group),
1-Amino-1,3,5,5-tetramethyl-3-ethylcyclohexane (mixture of diastereomers),
1-Amino-1,3,5-trimethylcyclohexane (mixture of diastereomers),
1-Amino-1,3-dimethyl-3-propylcyclohexane (mixture of diastereomers),
1-Amino-1,3 (trans),5 (trans)-trimethyl-3(cis)- propylcyclohexane,
1-Amino-1,3-dimethyl-3-ethylcyclohexane,
1-Amino-1,3,3-trimethylcyclohexane,
1-Amino-1,3 (trans)-dimethylcyclohexane,
1-Amino-1-methyl-3 (trans) propylcyclohexane,
1-Amino-1-methyl-3 (trans) ethylcyclohexane,
1-Amino-1,3,3-trimethyl-5 (cis) ethylcyclohexane,
1-Amino-1,3,3-trimethyl-5 (trans) ethylcyclohexane,
N-methyl-1-Amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1-methylcyclohexane,
N,N-dimethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1,5,5-trimethyl-3(cis)-isopropyl-cyclohexane,
1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane,
1-Amino-1-methyl-3(cis)-ethyl-cyclohexane,
1-Amino-1-methyl-3(cis)-methyl-cyclohexane,
1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane, and

US Serial No. 09/597,102
Response and Amendment After Final of June 9, 2006
MERZ 30

N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine,

and optical isomers, enantiomers, hydrates and pharmaceutically-acceptable salts of any of the foregoing.

- 16 - (previously presented)

A method of Claim 1 wherein the compound is administered in the form of a pharmaceutical composition thereof comprising the compound in combination with one or more pharmaceutically-acceptable diluents, excipients, or carriers.

- 17 - (previously presented)

A method of Claim 15 wherein the compound is administered in the form of a pharmaceutical composition thereof comprising the compound in combination with one or more pharmaceutically-acceptable diluents, excipients, or carriers.

US Serial No. 09/597,102
Response and Amendment After Final of June 9, 2006
MERZ 30